(AOF) – Quantum Genomics has entered into exclusive negotiations with Vistacare Medical with the ambition of creating “a benchmark player in the management of complex wounds”. Vistacare is an unlisted French HealthTech developing a “revolutionary” technology for the treatment of these complex wounds, patented with CE marking and already implemented in several French hospitals. The transaction is expected to close in the fourth quarter of 2023. The name change from Quantum Genomics to Vistacare Medical is anticipated.
Quantum Genomics declares that it has extended financial visibility until the second quarter of 2024, with a consolidated cash position which will be estimated at 4.3 million euros at the closing date of the transaction.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
